Stockscreener 앱 받기
3.46
6.49%
-0.24
시간 외 거래:
3.60
0.14
+4.05%
전일 마감가:
$3.70
열려 있는:
$3.71
하루 거래량:
432.72K
Relative Volume:
2.07
시가총액:
$117.72M
수익:
$210.00K
순이익/손실:
$-10.12M
주가수익비율:
-11.41
EPS:
-0.3032
순현금흐름:
$-7.12M
1주 성능:
+0.00%
1개월 성능:
+24.01%
6개월 성능:
+12.34%
1년 성능:
+7.45%
1일 변동 폭
$3.33
$3.82
1주일 범위
$3.33
$3.89
52주 변동 폭
$2.32
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
명칭
Anixa Biosciences Inc
전화
408-708-9808
주소
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
3.46 | 125.89M | 210.00K | -10.12M | -7.12M | -0.3032 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-21 | 개시 | Maxim Group | Buy |
| 2022-12-23 | 개시 | Chardan Capital Markets | Buy |
| 2021-04-12 | 개시 | H.C. Wainwright | Buy |
Anixa Biosciences Inc 주식(ANIX)의 최신 뉴스
Anixa Biosciences (ANIX) CEO purchases 3,188 shares at $3.37 each - Stock Titan
Form 4 Anixa Biosciences Inc For: 27 July By Investing.com - Investing.com Canada
Anixa Biosciences CEO Amit Kumar buys $11,190 in company stock By Investing.com - Investing.com Canada
Anixa Biosciences CEO Amit Kumar buys $11,190 in company stock - Investing.com
Anixa Biosciences Inc (ANIX) CEO purchases 3,000 shares at $3.73 - Stock Titan
Anixa Biosciences, Inc. Revenue Breakdown – NASDAQ:ANIX - TradingView
Anixa Biosciences Inc (ANIX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ANIX|Anixa Biosciences Inc|Price:3.700|Chg%:-0.050 - TradingKey
TradingKey - TradingKey
ANIX|Anixa Biosciences Inc|Price:3.725|Chg%:+0.025 - TradingKey
ANIX|Anixa Biosciences Inc|Price:3.680|Chg%:-0.020 - TradingKey
Anixa Biosciences Inc (ANIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Anixa Biosciences Inc (ANIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance UK
New Strong Buy Stocks for July 22nd - The Globe and Mail
CEO Amit Kumar Increases Stake in Anixa Biosciences Inc - GuruFocus
3 Penny Stocks With Market Caps Over $100M To Consider - Sahm
Anixa Biosciences (ANIX) CEO buys 5,000 common shares - Stock Titan
Anixa Biosciences Inc. (ANIX) Q2 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline Advances - dars.gov.et
Anixa Biosciences CEO Amit Kumar acquires 5,000 common shares for $17,300 - Bitget
Insider Buying: Titterton Lewis H Jr Acquires Additional Shares of Anixa Biosciences Inc (ANIX) - GuruFocus
Anixa Biosciences (ANIX) director purchases 12,000 shares of common stock - Stock Titan
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance - AOL.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Anixa Biosciences Director Lewis H. Titterton Jr acquires $9,172 of common shares - Bitget
Anixa Biosciences director buys $9,174 in common stock By Investing.com - Investing.com South Africa
Insider Buying: Titterton Lewis H Jr Increases Stake in Anixa Bi - GuruFocus
Anixa Biosciences director buys $9,174 in common stock - Investing.com
Form 4 Anixa Biosciences Inc For: 16 July By Investing.com - Investing.com Canada
Director Lewis Titterton buys more Anixa Biosciences Inc (ANIX) stock - Stock Titan
Anixa Biosciences (ANIX) Secures New Patent for Breast Cancer Va - GuruFocus
Anixa Biosciences Secures Patent Approval in Australia for Breas - GuruFocus
Anixa Biosciences (ANIX) Secures New Patent for Breast Cancer Vaccine Technology - GuruFocus
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology - PR Newswire
Anixa Biosciences (ANIX) Faces Modest Decline, Testing Key Support at $2.89Percent Above MA - dars.gov.et
CEO Amit Kumar Increases Stake in Anixa Biosciences Inc with Rec - GuruFocus
Form 4 Anixa Biosciences Inc For: 13 July By Investing.com - Investing.com Nigeria
Anixa Biosciences CEO Amit Kumar buys $15,200 in stock By Investing.com - Investing.com Canada
Anixa Biosciences (ANIX) CEO Amit Kumar buys 5,000 shares at $3.04 - Stock Titan
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Trial to Highest Dose Cohort - HLTH
Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial - Moomoo
Anixa doses first patient in highest cohort of ovarian trial By Investing.com - Investing.com South Africa
Anixa doses first patient in highest cohort of ovarian trial - Investing.com
Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level. - Bitget
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date - PR Newswire
ANIXAnixa Biosciences Inc Revenue Breakdown - Finviz
D. Boral Capital Initiates Anixa Biosciences(ANIX.US) With Buy Rating, Announces Target Price $10 - Moomoo
Here's why you should add ANIX stock to your portfolio now - MSN
ANIX Assumed by D. Boral Capital -- Rating Maintained at Buy - GuruFocus
Anixa Biosciences Price Target Maintained With a $10.00/Share by D. Boral Capital - Moomoo
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 - AOL.com
Anixa Biosciences Inc (ANIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):